// App-Quantinova.ai

4886 : PEGylated recombinant hyaluronidase PH20 (PEGPH20) enhances checkpoint inhibitor efficacy in syngeneic mouse models of cancer

Researchers

Presenter

  • Sanna Rosengren

Principal Investigators

  • Renee Clift

  • Susan J. Zimmerman

  • Jennifer Souratha

  • Benjamin J. Thompson

  • Barbara Blouw

  • Xiaoming Li

  • Qiping Zhao

  • Michael Shepard

  • Dan C. Maneval

  • Christopher D. Thanos

  • Curtis B. Thompson

Medical Centers

  • Halozyme Therapeutics, San Diego, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Hyaluronic acid

  • Interleukin 10

Drug/Treatment

  • PEGPH20

  • Hyaluronic acid

  • Anti-CTLA4

  • Interleukin-10

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved